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Case Report
Continuous Glucose Monitoring System — Useful but
Expensive Tool in Management of Diabetes
K Vidhya, R Sudhir, V Mohan
Abstract
Until recently, self monitoring of blood glucose (SMBG) was the only tool used for monitoring blood
glucose levels.  The limitation of SMBG is that it cannot continuously monitor blood glucose levels. In
this paper, we present our initial experience with the continuous glucose monitoring system (CGMS)
in three different clinical situations.  With reduction in cost and further refinement in technology,
CGMS could become a valuable tool for clinical practice and research studies in diabetes. ©
INTRODUCTION
Recent reports from various trials such as Diabetes Controland Complications Trial (DCCT)1 have demonstrated the
importance of tight glycemic control in the prevention of
complications of diabetes. Indeed, it is now accepted that the
cost of treating the complications of diabetes far exceeds
that of regular monitoring and therapy of diabetes.
Self monitoring of blood glucose (SMBG) has today
become an integral part of the diabetes management. However,
SMBG only gives blood sugars at the different points of time
when the patient chooses to test the blood sugar.  It is possible
that there could be occasions during the day or night when
the blood sugars may go very high or low and these peaks
and valleys can be completely missed even in patients who
perform SMBG regularly. Often, Somogyi syndrome or
rebound hyperglycemia following an episode of
hypoglycemia is clinically suspected but difficult to prove
because of the non-availability of continuous blood glucose
monitoring. The advantage of monitoring blood glucose levels
continuously are therefore obvious but till recently, this had
remained the diabetologist’s dream.
Continuous ambulatory blood pressure monitoring and
holter monitoring have been available for quite some time.
There has been a long felt need for a similar device which
could monitor blood glucose on a continuous basis and give
us an insight into the trend of the blood glucose levels on a
24 hour basis. After decades of research, such systems have
finally seen the light of day. Continuous glucose monitoring
system, (CGMS) is one of the first such devices to become
commercially available to monitor glucose levels on a
continuous basis for upto 72 hours.  It was approved by the
M.V. Diabetes Specialities Centre and Madras Diabetes  Research
Foundation Gopalapuram, Chennai, India.
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Food and Drugs Administration (FDA), U.S.A. in June 1999
and it has been successfully used in several centres abroad
for evaluation of diabetic patients during the last one to two
years.
The CGMS unit consists of a glucose sensor, which is
inserted into the subcutaneous tissue of the body and left in
place for upto 72 hours. This sensor senses the interstitial
fluid glucose levels electrochemically every 10 seconds and
records an average value every 5 minutes and gives 288 values
per day.  These glucose values are recorded on a monitor,
which is the size of a pager.  Finger-stick blood glucose values
are also entered into the monitor for calibration purpose and
a minimum of four values per day are needed for accurate
calibration. Events like exercise, food intake, insulin delivery
and hypoglycemic episodes can also be entered in the
monitor.  After 72 hours, the sensor is removed and the data
from the monitor is downloaded into a PC, which gives a
continuous graph of the glucose values of the previous 3
days with the finger-stick values and the events plotted in
time.
CGMS was introduced at the M.V.Diabetes Specialities
Centre, Gopalapuram, Chennai in August 2002 and we started
using this technology to evaluate patients whose blood
sugars are poorly controlled despite optimal treatment.  In
this report, we present our initial experience with CGMS which
we believe is the first report of CGMS from India.
CASE 1
This is a 45 year old lady with Type 2 diabetes mellitus of
10 years duration. She was highly motivated to control her
diabetes and was doing regular SMBG based on which she
adjusted her insulin doses. She was on oral agents in addition
to three insulin injections per day. However she complained
of repeated hypoglycemic symptoms and blood tests revealed
fluctuating fasting plasma glucose values with consistently
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high postprandial values and several episodes of
hypoglycemia.
After initially adjusting her dosage of insulin with short
acting insulin injections with breakfast and lunch, and a mixture
of short and intermediate acting insulins with dinner, we
started her on CGMS.
Fig. 1a shows the first day’s CGMS profile.  It shows a low
sugar reaction around 2 to 3 AM followed by a spurt in blood
sugar around 6 AM which further rises to a high value of
around 300 mg by about 10.AM. As the morning insulin took
effect, there was an another hypoglycemic episode around
noon with another surge after lunch.  The dose of intermediate
insulin at night was reduced and this prevented the early
morning hypoglycemia the next day as shown in Fig. 1b.
However the day time control was still not sufficient.  After
the morning dose was readjusted, a much smoother profile of
blood glucose levels were obtained on Day 3 (Fig. 1c).
CASE 2
This is a 12 yr old female child with recently detected Type
1 diabetes mellitus. She was on once a day premixed insulin
at bed time which was started by a local physician before she
came to our centre.  Her HbA1c was 18%. Fig. 2a shows the
atrocious control of diabetes with hypoglycemic episodes in
the night and day time with sugars hovering between 200 to
over 400 mg/dl (note upper limit of CGMS is 400 mg/dl). She
was started on a TDS insulin regime.  After addition of the
morning and noon doses of insulin, the daytime control
considerably improved (Fig. 2b). However, she still had an
episode of hypoglycemia at midnight followed by a Somogyi
syndrome which was corrected the next day by adjusting the
night dose of insulin (data not shown).
In this case, CGMS proved to be a great motivating tool
for the parents and  the girl to accept the TDS insulin regime
and on follow-up after 4 months her  HbA1c had dropped to
7.5%.
CASE 3
This patient is a late onset Type 1 diabetes mellitus of 11
years duration who was unable to get his HbA1c below 10%
even with multiple injections and different insulin regimens.
During his first visit his HbA1c was 11.8%. He was motivated
and advised to use continuous subcutaneous insulin
infusion(CSII). He was admitted for demonstration and
initiation of CSII.  On the day of admission, CGMS was started
(Day 1) while he was on a four times a day insulin regime and
this was continued on Day 1 and Day 2. Fig. 3a (Day 1) and b
(Day 2) shows how bad his control was even with four times
Fig. 1a : Day 1 of Case 1.
Fig. 1b :  Day 2 of Case 1.
Fig. 1c :  Day 3 of Case1.
Fig. 2a :  Day 1 of Case 2.
Fig. 2b :  Day 2 of Case2
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insulin per day.  CSII was initiated around 8 PM on Day 2.  He
was started on a fixed basal rate with dual wave boluses of
Lispro insulin with meals.  While on CSII, patient was also
allowed to take his usual food and was taught to adjust his
bolus doses by himself based on SMBG values. With initiation
of CSII, the glycemic control got better and the fluctuations
were largely eliminated and the blood sugars became near
normal (Fig. 3c and 3d).
After seeing the results of the CGMS, the patient was
very much convinced about the usefulness of CSII and for
the past several months has been using CSII and his HbA1c
has improved considerably.
DISCUSSION
In this report, we presented three different clinical
situations where we have used CGMS and derived benefit to
achieve better control of diabetes.  We have now used CGMS
in many more patients and have found it to be a very useful
tool both to learn more about the patient’s diabetic status
and also to educate and motivate the patient to achieve tight
control.  Table 1 summarizes some of the situations where we
believe CGMS may be useful.
Table 1 : Clinical uses of CGMS
1. Continuous assessment of glycemic trends and patterns
2. Detection of unexpected and unrecognized hypoglycemia.
3. Checking adequacy of treatment regimens
4. To study the glycemic indices of various food stuffs
5. For achieving better programming of the insulin pump (CSII).
CGMS is a relatively new inclusion into the armamenterium
of monitoring devices and the experience with its usage is
rather limited.  We reveiwed the  current literature which carry
reports on the utility of CGMS. Kaufman2 and Bode and
Hirsch3 used the CGMS on Type 1 diabetic subjects and
concluded that CGMS helped to identify glycemic pattern in
them and was useful to adjust therapy. Boland and
Tomborlane4 used the CGMS graphs to educate and motivate
young Type 2 diabetic patients about healthy lifestyle and
diet practices.  Moghissi and Mestman5 have reported that in
Type 2 diabetic patients, CGMS revealed postprandial
hyperglycemia and noctural hypoglycemia which was missed
by conventional testing. Jovanovic6 monitored glycemic
status in gestational diabetic patients and states that CGMS
findings are useful in educating the patient about behaviour
modifications that are needed to achieve tight glycemic
control and prevent macrosomia.
Thus it is clear that CGMS is very helpful in many situations
where we need to achieve good control.  However, it is
currently expensive, especially in a developing country like
India. It requires at least four SMBG readings per day which
need to be entered into the CGMS monitor against which the
sensor calibrates the readings done. Unless four SMBG
readings are done, the profile obtained may not be reliable
and this adds to the cost of the treatment.
The CGMS unit itself currently cost around Rs. 2.5 lakhs
and the sensor costs around Rs 4200/- and hence a 3 day
Fig. 3a : Day 1 of Case 3.
Fig. 3b : Day 2 of Case 3.
Fig. 3c : Day 3 of Case 3.
Fig. 3d : Day 4 of Case 3.
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study wth CGMS would prove to be quite costly for the
average Indian.
Another major drawback of CGMS is that the glucose
profile needs to be downloaded on to a computer only after
disconnecting the sensor from the patient.  Therefore, it does
not give a real time display of the trend which will assist us to
adjust therapy immediately and the results are available only
after the CGMS is disconnected after 72 hours.  Thus if further
modifications need to be  done based on the CGMS findings
and this needs to be documented, the patient needs to
undergo CGMS again which increases the cost factor
considerably.  Finally the upper limit of blood sugar in CGMS
is currently 400 mg/dl and if this could be set at a much higher
level, it would be possible to detect wide fluctuations of blood
sugar.
In conclusion, CGMS has made the dream of the
diabetologist to measure glucose levels continuously a reality.
It is to be hoped that in the years to come, reduction in the
costs and further improvements in technology would ensure
more widespread use of this potentially exciting method of
continuously monitoring glucose levels. We need to identify
those patients who will be benefited by CGMS. As it is a new
technology, the health care professionals using CGMS have
to become familiar with it and feel comfortable to use it on
patients. The cost of any new technology is inevitably high
and CGMS is no exception. There is no doubt that the
information that CGMS gives is very valuable in improving
the treatment and quality of life of the patient and his/her
own understanding of the diabetes, which outweighs the
cost involved, atleast in selected patients.
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Announcement
Conference on Idiopathic Thrombocytopenic Purpura (ITP)
Dr. JC Patel Medical Research Foundation and Smt SC Mehta Hematology Department, BSES MG
Hospital, are organizing a Conference on ITP on 9,10, October, 2004 in Mumbai. Topics to be covered
in the conference are - Pathogenesis of thrombocytopenia, ITP in children, ITP in adults, Problems in ITP,
Clinical diagnosis of ITP, Laboratory diagnosis of ITP, Special investigations in ITP, Differential diagnosis
of ITP, Problem solving in ITP, Objectives of treatment in ITP, Treatment of acute ITP, Treatment of
chronic ITP, Treatment of refractory ITP, Role of ivIg in treatment of ITP, Family physician and ITP,
Problems of ITP in obstetric-gynec practice, ITP and menorrhagia, ITP in pregnancy, ITP and surgeon,
Splenectomy in ITP, Laparoscopic splenectomy in ITP, Surgery in patients with ITP, ITP and lay people.
It is proposed to form ITP Study Group and ITP Support Group during the conference. All clinicians who
deal with ITP patients would benefit from the conference.
For further details contact : Prof. BC Mehta, BSES MG Hospital, SV Rd, Andheri West, 400 058.
E-mail : labmed@ghrc-bk.org
